Benton Davies

• Promoted to lead product strategy and execution for the NovaSeq X Series, overseeing roadmap decisions across hardware, chemistry, and software for Illumina’s highest-throughput sequencing platform.
• Restructured the product team into domain-specific ownership (hardware, chemistry, software) and hired two new product managers, improving collaboration between on-market and NPI teams and accelerating roadmap execution through tighter engineering alignment.
• Led cross-functional execution of the NovaSeq X 1.3 release, partnering with R&D, engineering, support, and marketing to resolve platform-blocking issues—resulting in a 2x increase in flow cell utilization and renewed customer momentum.
• Ran a multi-site alpha program with 14 strategic customers to validate and refine 1.3 improvements, focusing on run success rate, pass filter consistency, and output stability—ensuring platform KPIs were met and restoring confidence in NovaSeq X performance.
• Established a structured process to triage and prioritize the top 5 customer-reported blockers, ensuring engineering teams had visibility and accountability—leading to timely delivery of critical fixes and improved customer trust.
• Reset the NovaSeq X roadmap by aligning development priorities with revenue-driving customer segments and applications—including service providers, core labs, reference labs, and clinical users focused on MRD, counting, and screening workflows.

• Worked directly with Nashville Biosciences and Singapore PRECISE, partnering with development to shape the cohort analysis product that ultimately supported >$100M in revenue and helped onboard 6 global pharma partners.
• Designed and launched a cohort builder used by global PopGen programs, pharma, and academic medical centers to stratify patients at scale — driving >200% QoQ growth and adoption 191% above forecast.
• Implemented OMOP across core clinical domains (Person, Condition, Procedure, Measurement, Drug) to support longitudinal analysis for real-world data applications.
• Mapped clinical ontologies (ICD-10, SNOMED, HPO, MeSH) into the platform to simplify how pharma teams could query genomic data with clinically relevant codes.
• Served as the product lead connecting engineering, R&D, and field teams, translating complex customer needs into executable, scalable roadmap priorities.
• Kept renewal rates above 95% by staying close to the field, incorporating VOC into roadmap decisions, and fixing workflow blockers quickly.

• Introduced an Automation Platform portfolio for germline and somatic RUO liquid reagent workflows.

- Led the GTM strategy for co-selling automation scripts with 3rd party liquid handling vendors.

• Drove strategic direction and roadmap development/execution for IVD Cloud Platform, taking into account regional regulatory, data privacy, and residency requirements, enabling a path for global commercialization of NVTA’s NGS-based IVD offering.

-Led the development of the GTM strategy for the software component of Invitae’s solid tumor and liquid biopsy CE-IVD product launched in EMEA -Conducted VOC and gathered stakeholder input to ensure customer-centric product development for the Cloud and Automation Platforms

• Partnered and collaborated deeply with technical leads to define API specifications and other service integration points enabling an optimized customer experience through easy, frictionless access to QC, patient results, and PDF reports seamlessly integrated into their LIMS and EHR

systems

• Managed an on-market IVD (assay + SW) in Japan, driving growth through collaboration and implementation with assay development, software, product support, and regional commercial teams. -Increased volume and customer satisfaction through improved coordination with pharma partners and internal stakeholders

• Manage a portfolio of custom application panels and software services by leading activities around go-to-market strategy, sales/field support, and delivering on KPI's. Impact: Grew managed portfolio value 201% YOY (through Q3 of 2020)

•Managed concept-to-launch of a SaaS platform that enables customers to design custom tests in-house for use on Agena's system. To successfully launch on time, I defined product requirements by conducting qualitative/quantitative voice of customer research, competitive analysis

and led the global commercial training. Impact: Led to a 22% increase in user engagement with the software service ($450K in revenue)

•Led the development of a suite of HTML software analysis reporters providing customers a simpler view for reviewing dense sample data results. These reporters allow users to accelerate their sample reporting turnaround time and increase daily throughput. Impact: Achieved 90%

customer adoption in the new reporters

•Launched a customer experience journey, which is a program that allows customers to track the progress of their custom panel design in real-time. Tracked customer satisfaction via NPS survey showing QOQ improvement since launch. Impact: $1.1M+ in repeat purchase order

commitments since program launch

•Implemented account-based marketing tactics around Agena’s Custom Applications portfolio. Impact: Drove 30% in increased engagement through digital marketing channels (email, content marketing, PPC, SEO)

• Built a prospect database by partnering with sales to interface with strategic accounts to gather insights for upcoming product launches about target customer profiles in the life sciences, healthcare, and pharma industries

•118% to plan in 2017-2018 for a $3.5MM territory plan (95+ mid-market and enterprise accounts in the Americas region).

•Grew a $4.6MM global customer support business 12% growth by consolidating service plan offerings to better fit the needs of our growing clinical customers base. This restructure increased support contract coverage 10% globally across AMR, EMEA, APAC, and Greater China.

•Identified strategic partnership opportunities ($1.5MM in pipeline opportunities) to expand the utilization of Agena's products in the molecular genetics market.

•Increased systems revenue >$700K by developing a global “competitive displacement program” to place Agena's system in strategic clinical labs for no charge in exchange for reagent commitments; included metrics for concordance studies and cost calculators to remove the barriers

when a lab is switching technologies.

• Constructed a market growth model. - Deployed and conducted a quantitative survey, contrasting data with historical financial records offering insights into qPCR market trends.

• Developed customer experience evaluation platform. - Created qualitative survey and NPS questions and executed the first annual deployment to identify instrument/software enhancement opportunities.